Dubai – July 2025 – Healthtech innovator Valeo Health ME has successfully raised $12 million in Series B financing, marking a major milestone in its mission to offer advanced, AI-powered wellness and longevity services across the Middle East. This fresh capital comes from both existing supporters and new strategic investors, bringing total funding to around $20 million.
Redefining Preventive Healthcare with Intelligent Technology
Founded in 2021, Valeo Health ME designs personalized care pathways using artificial intelligence and data from remote diagnostics. Its service model combines home-based health assessments, tailored lifestyle guidance, and ongoing digital monitoring—all curated to prevent health issues before they arise.
With this funding, the company plans to bolster its proprietary AI algorithms, expand direct-to-consumer diagnostic services, and deepen its clinical reach throughout the Gulf region.
Purposeful Expansion in the GCC
The funding round will accelerate the company’s footprint in the UAE and facilitate its debut in Saudi Arabia, with a vision to scale services across other GCC countries. Key priorities include:
- Enhancing AI-driven diagnostic accuracy and predictive health modeling
- Developing new capabilities, such as remote monitoring tools and personalized longevity plans
- Growing specialized teams in clinical operations, data science, and regional business development
This emphasis reflects a shift toward prevention-focused healthcare, meeting growing demand for personalized wellness solutions outside traditional medical settings.
Why This Matters
Gulf countries are undergoing a healthcare transformation, placing increased importance on wellness, longevity, and digital innovation. Valeo’s platform integrates science-driven preventive strategies with one-on-one guidance and real-time AI analytics, addressing a rising need for accessible, high-quality remote care.
Strategic Momentum and Outlook
With approximately $20 million in total funding, Valeo Health ME ranks among the most well-funded healthtech startups in its region. The Series B lift positions the company to partner with insurers and large healthcare providers, expand care delivery programs, and introduce complementary telehealth services.
Bottom Line
Valeo Health ME’s Series B round underscores the growing importance of AI-powered, preventive health platforms in the GCC. By offering personalized care plans and remote diagnostics, the company is charting a new path in regional healthcare—one that moves from reactive treatment to proactive, data-informed wellness.